- Home
- FENC vs MITT Comparison
FENC vs MITT Comparison
Compare FENC & MITT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | MITT |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.5M | 258.7M |
| IPO Year | 2001 | 2011 |
Fundamental Metrics
Financial Performance| Metric | FENC | MITT |
|---|---|---|
| Price | $7.58 | $8.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $13.50 | $8.70 |
| AVG Volume (30 Days) | 154.3K | ★ 207.5K |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 10.44% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.94 |
| Revenue | $38,790,000.00 | ★ $87,678,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $75.22 | $16.68 |
| P/E Ratio | ★ N/A | $9.39 |
| Revenue Growth | N/A | ★ 8.59 |
| 52 Week Low | $4.68 | $5.63 |
| 52 Week High | $9.92 | $8.91 |
Technical Indicators
Market Signals| Indicator | FENC | MITT |
|---|---|---|
| Relative Strength Index (RSI) | 45.98 | 75.17 |
| Support Level | $7.50 | $8.32 |
| Resistance Level | $8.00 | $8.22 |
| Average True Range (ATR) | 0.29 | 0.15 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 43.08 | 88.57 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About MITT AG Mortgage Investment Trust Inc.
AG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. It also focuses on investing in residential mortgage-backed securities (RMBS) issued or guaranteed by a government-sponsored enterprise.